Medtronic plc has reported its financial results for the third quarter of fiscal year 2026, showing an 8.7% increase in revenue as reported and a 6.0% rise on an organic basis compared to the same period last year. The company’s worldwide revenue reached $9.017 billion for the quarter ending January 23, 2026.
The cardiovascular portfolio led growth with an 11% year-over-year increase, while Cardiac Ablation Solutions grew by 80%, driven by strong performance in pulsed field ablation products. The diabetes business also saw notable gains, with revenue rising by 8.3%, particularly due to double-digit growth in international markets.
Geoff Martha, Medtronic chairman and chief executive officer, stated: “Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio. By unlocking new markets and investing in high-growth opportunities, we are accelerating performance across the company. Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long-term growth. It’s an exciting time for Medtronic.”
The company achieved a GAAP diluted earnings per share (EPS) of $0.89 and a non-GAAP diluted EPS of $1.36 for the quarter, surpassing its guidance midpoint by three cents.
Medtronic reiterated its full-year guidance for fiscal year 2026, expecting approximately 5.5% organic revenue growth and non-GAAP diluted EPS between $5.62 and $5.66.
Thierry Piéton, chief financial officer at Medtronic, commented: “This quarter, we again delivered accelerated growth while investing decisively in our future. We continued to invest in R&D to strengthen our innovation pipeline, funded significant growth opportunities while driving G&A leverage, and we executed on our M&A and venture strategy with two key transactions in the quarter. Bottom line, we are executing on our roadmap and positioning the business for sustainable growth.”
During the third quarter, Medtronic secured several regulatory clearances including CE Mark approval for Sphere-360 and U.S. FDA clearance for both Hugo robotic-assisted surgery systems—where first cases have already been completed—and Stealth AXiS Surgical System for spinal procedures.
The company also advanced its merger-and-acquisition strategy with two significant transactions: acquiring CathWorks in Coronary and Renal Denervation as well as Anteris in Structural Heart.
A video webcast discussing these results was scheduled for February 17 at investorrelations.medtronic.com; replays will be available online along with detailed financial schedules.
Medtronic is headquartered in Galway, Ireland and operates globally across more than 150 countries with over 95,000 employees.
